Trial Profile
A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study of AIR645 in Healthy Subjects and Subjects With Controlled Asthma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs AIR 645 (Primary)
- Indications Asthma
- Focus Adverse reactions
- 15 Sep 2009 Results were presented at the European Respiratory Society Annual Congress in Vienna, according to a Altair Therapeutics media release.
- 26 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 May 2009 Results have been presented at the 2009 International Conference of the American Thoracic Society within a Mini-Symposium according to an Altair Therapeutics media release. Results were also reported in the media release.